Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 2, 2003

View Archived Issues

Drug pipeline for acute respiratory distress syndrome

Antitumor efficacy of virotherapy plus chemotherapy in gastrointestinal tumors

Good safety profile reported for the antioxidant CPI-1189 in HIV-associated neurotoxicity

Antitumor activity reported for CCI-779 in advanced/metastatic breast cancer

Novel paclitaxel formulation ABI-007 evaluated in cancer patients

MaxCyte launched as independent biotech company

Icos discontinues phase III trial of Pafase following independent interim analysis

GlycoGenesys acquires Elan's interest in joint venture

PSMA Development prostate cancer vaccine enters phase I

Onconase receives fast track designation for malignant mesothelioma

Acologix begins phase I trial of dentonin

BMS submits NDA for atazanavir for treatment of HIV

Cidecin NDA submitted for complicated skin and skin structure infections

U.S. and E.U. filings made for HIV treatment GW-433908

FDA approval for Xalatan as first-line therapy for elevated IOP

Once-daily Depakote ER approved for certain forms of epilepsy

E.U. approval obtained for once-weekly Actonel/Optinate for postmenopausal osteoporosis

Casodex 150 mg not recommended for use in U.S. in early prostate cancer

New company specializing in drugs for organ transplantation

Gleevec granted FDA approval for first-line treatment of CML

New caspase activators and their use in cancer and autoimmune diseases

Novel p38 kinase inhibitors prepared and tested at Teikoku Hormone

Antiviral compounds able to inhibit membrane fusion events claimed by Trimeris

Discovery of Src kinase inhibitors reported by AstraZeneca

CV Therapeutics seeks approval for Ranexa for chronic angina

Taisho presents arginine-based MC4 receptor ligands

Novel agents for gene delivery designed by Transgene researchers

Isis Pharmaceuticals reacquires ISIS-113715 from Merck

Popular Stories

Today's news in brief
BioWorld
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
University of Southern California reports new MAPT aggregation inhibitors
BioWorld Science
The University of Southern California has identified (2-oxo-2H-chromen-3-yl) scaffold-based carboxamide analogues acting as potent microtubule-associated protein...